A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects.

NCT06147544 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Obesity

Interventions

DRUG: PB-718
DRUG: Placebo

Sponsor

PegBio Co., Ltd.